Menu
GWAS Study

Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture.

Stuart PE, Nair RP, Tsoi LC et al.

26626624 PubMed ID
GWAS Study Type
23650 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

SP
Stuart PE
NR
Nair RP
TL
Tsoi LC
TT
Tejasvi T
DS
Das S
KH
Kang HM
EE
Ellinghaus E
CV
Chandran V
CK
Callis-Duffin K
IR
Ike R
LY
Li Y
WX
Wen X
EC
Enerbäck C
GJ
Gudjonsson JE
KS
Kõks S
KK
Kingo K
ET
Esko T
MU
Mrowietz U
RA
Reis A
WH
Wichmann HE
GC
Gieger C
HP
Hoffmann P
NM
Nöthen MM
WJ
Winkelmann J
KM
Kunz M
ME
Moreta EG
MP
Mease PJ
RC
Ritchlin CT
BA
Bowcock AM
KG
Krueger GG
LH
Lim HW
WS
Weidinger S
WM
Weichenthal M
VJ
Voorhees JJ
RP
Rahman P
GP
Gregersen PK
FA
Franke A
GD
Gladman DD
AG
Abecasis GR
EJ
Elder JT
Chapter II

Abstract

Summary of the research findings

Psoriasis vulgaris (PsV) is a common inflammatory and hyperproliferative skin disease. Up to 30% of people with PsV eventually develop psoriatic arthritis (PsA), an inflammatory musculoskeletal condition. To discern differences in genetic risk factors for PsA and cutaneous-only psoriasis (PsC), we carried out a genome-wide association study (GWAS) of 1,430 PsA case subjects and 1,417 unaffected control subjects. Meta-analysis of this study with three other GWASs and two targeted genotyping studies, encompassing a total of 9,293 PsV case subjects, 3,061 PsA case subjects, 3,110 PsC case subjects, and 13,670 unaffected control subjects of European descent, detected 10 regions associated with PsA and 11 with PsC at genome-wide (GW) significance. Several of these association signals (IFNLR1, IFIH1, NFKBIA for PsA; TNFRSF9, LCE3C/B, TRAF3IP2, IL23A, NFKBIA for PsC) have not previously achieved GW significance. After replication, we also identified a PsV-associated SNP near CDKAL1 (rs4712528, odds ratio [OR] = 1.16, p = 8.4 × 10(-11)). Among identified psoriasis risk variants, three were more strongly associated with PsC than PsA (rs12189871 near HLA-C, p = 5.0 × 10(-19); rs4908742 near TNFRSF9, p = 0.00020; rs10888503 near LCE3A, p = 0.0014), and two were more strongly associated with PsA than PsC (rs12044149 near IL23R, p = 0.00018; rs9321623 near TNFAIP3, p = 0.00022). The PsA-specific variants were independent of previously identified psoriasis variants near IL23R and TNFAIP3. We also found multiple independent susceptibility variants in the IL12B, NOS2, and IFIH1 regions. These results provide insights into the pathogenetic similarities and differences between PsC and PsA.

1,363 European ancestry cases, 4,934 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

23650
Total Participants
GWAS
Study Type
Yes
Replicated
up to 2,969 European ancestry cases, up to European ancestry 14,384 controls
Replication Participants
European
Ancestry
U.S., Canada, Germany, Estonia, Australia, New Zealand
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.